In notable contrast to the increased IgG3 concentrations in both mild and severe COVID-19 cases (Fig. 2b), IgG3 showed a trend to being lower in patients developing PACS (Fig. 2d, f). The gene discussed is IGHG3; the disease is COVID-19.